fig7

Figure 7. The combination of alpelisib with fulvestrant induces a synergistic effect that is further enhanced by the addition of AZD4547. (A) Fulvestrant-induced inhibition of MCF7/C and MCF7/FGFR1 cells. Cells were treated with fulvestrant at the indicated concentrations for 5 days, followed by CCK-8 assays. IC₅₀ values were analyzed with GraphPad; (B and C) Synergistic effect of alpelisib with fulvestrant in MCF7/C (B) and MCF7/FGFR1 (C) cells. Cells were treated with alpelisib (Alp) and fulvestrant at the indicated concentrations for 5 days, followed by CCK-8 assays. CI values were calculated using CompuSyn software according to the Chou-Talalay method. Only CI values corresponding to a fractional effect (FA) greater than 0.5 were presented; (D and E) Addition of AZD4547 (AZD) further enhances the alpelisib-fulvestrant (Alp-Ful) combination in four different treatment regimens. MCF7/C (D) and MCF7/FGFR1 (E) cells were treated with AZD4547 and four different combinations of alpelisib and fulvestrant at the indicated concentrations for 5 days, followed by CCK-8 assays. CI values were calculated as above.